Health Care [ 4/12 ] | Life Sciences Tools & Services [ 21/72 ]
NASDAQ | Common Stock
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally.
The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
It offers clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; and clinical research services, including biostatistics, clinical operations, clinical supplies management, covid-19, data management, decentralized & hybrid clinical solutions, endpoint adjudication services, interactive response technologies, investigator payments, medical affairs, medical writing and publishing, pharmacovigilance, and site and patient solutions.
The company also provides laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers.
In addition, it offers commercial positioning, early phase, language, medical imaging, and strategic solutions, as well as clinical trial management, consulting, and contract staffing services.
The company serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations.
ICON Public Limited Company was incorporated in 1990 and is headquartered in Dublin, Ireland.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jul 24, 24 | 3.75 Increased by +20.58% | 3.68 Increased by +1.90% |
| Apr 24, 24 | 3.47 Increased by +19.66% | 3.41 Increased by +1.76% |
| Mar 12, 24 | 3.46 Increased by +10.54% | 3.44 Increased by +0.58% |
| Oct 25, 23 | 3.30 Increased by +10.00% | 3.28 Increased by +0.61% |
| Jul 26, 23 | 3.11 Increased by +8.74% | 3.08 Increased by +0.97% |
| Apr 26, 23 | 2.90 Increased by +5.07% | 2.88 Increased by +0.69% |
| Feb 22, 23 | 3.13 Increased by +19.01% | 3.05 Increased by +2.62% |
| Nov 2, 22 | 3.00 Increased by +17.65% | 2.94 Increased by +2.04% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 2.06 B Increased by +5.80% | 163.66 M Increased by +2.19% | Increased by +7.96% Decreased by -3.41% |
| Jun 30, 23 | 2.02 B Increased by +4.40% | 115.60 M Decreased by -0.12% | Increased by +5.72% Decreased by -4.32% |
| Mar 31, 23 | 1.98 B Increased by +4.04% | 116.65 M Increased by +4.18% | Increased by +5.90% Increased by +0.14% |
| Dec 31, 22 | 1.96 B Increased by +4.08% | 117.44 M Increased by +53.59% | Increased by +5.99% Increased by +47.57% |
| Sep 30, 22 | 1.94 B Increased by +4.08% | 160.15 M Increased by +269.89% | Increased by +8.25% Increased by +263.23% |
| Jun 30, 22 | 1.94 B Increased by +122.14% | 115.73 M Increased by +56.68% | Increased by +5.98% Decreased by -29.47% |
| Mar 31, 22 | 1.90 B Increased by +121.60% | 111.97 M Increased by +15.29% | Increased by +5.89% Decreased by -47.97% |
| Dec 31, 21 | 1.89 B Increased by +147.97% | 76.47 M Decreased by -24.46% | Increased by +4.06% Decreased by -69.54% |